marijuana stocks news

American Cannabis Company, Inc. (AMMJ)

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 640   (3,848) 2,585   1,881  
Cost of Revenue 416 (3,683) 2,180 1,859
Gross Profit 224   (164) 406   22  
Operating Expenses
Research Development 13 – – –
Selling General and Administrative 3,588 (1,758) 1,752 283
Non Recurring – – – –
Others – – – –
Total Operating Expenses – – – –
Operating Income or Loss (3,377) 1,594   (1,346) (262)
Income from Continuing Operations
Total Other Income/Expenses Net – – 96 –
Earnings Before Interest And Taxes (3,605) 1,497 (1,250) (262)
Interest Expense (1) (82) 49 34
Income Before Tax (3,604) 1,579 (1,299) (296)
Income Tax Expense – – 12 (65)
Minority Interest – – – –
Net Income From Continuing Ops (3,569) 1,526 (1,311) (231)
Non-recurring Events
Discontinued Operations – – – –
Extraordinary Items – – – –
Effect Of Accounting Changes – – – –
Other Items – – – –
Net Income (3,604) 1,526   (1,311) (231)
Preferred Stock And Other Adjustments – – – –
Net Income Applicable To Common Shares (3,604) 1,526   (1,311) (231)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

GT Biopharma Inc. (OXIS) Executives to Present at Rodman & Renshaw Conference in New York

GT Biopharma (OXIS) Executives to Present at Rodman & Renshaw Conference in…

GT Biopharma Inc. (GTBP) Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease

GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis…

Cara Therapeutics, Inc. (CARA) Announces Completion of Interim Statistical Assessment

Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in…